Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding
Dear members of NASC,
Members of all National Anaesthesia Societies are invited to comment on the new draft guidelines “Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding” and we would appreciate your input.
These guidelines are produced as a service to ESAIC members and are offered to national anaesthesia societies for local adaptation as desired.
You can access the draft guideline directly on this link.
This document will be available until 14 September 2023. You are invited to comment on the draft guideline through the online comment form.
We would be especially interested to read your thoughts on the following points:
· Practicality: How well do the guidelines address everyday situations and problems in this area?
· Readability: Are the guidelines easy to read? Do they make sense?
· Presentation: Is the layout clear?
· Acceptability and generalizability: Do they fit into practice in your own country? Would the guidelines as written cause problems, or antagonise anyone?
Finally, please declare any conflicts of interests (e.g. relevant industry connections or funding) when you submit your comments as these will be shared with the authors.
The guideline will be available for comment for 4 weeks from the date of this email.
All comments will be received by Dr. Oliver Grottke, Chairperson of the Task Force for this guidelines.
Many thanks for your help.
Chair, ESAIC Guidelines Committee
If you have any questions, please contact us at firstname.lastname@example.org
Survey SFAR: The use of OFA in 2020 in France
The evaluation of the actual diffusion in 2020, the use of OFA, used molecules and the used modalities. Click here to start the survey.
SARB recommendations for the anesthetic management of patients suspected of being infected or infected by the new coronavirus initially named 2019-nCoV
(last update: 3/04/ 2020 17:30)
(last update: 30/03/ 2020 14:00)
We would like you to consider participating in the BlueBerry study. This academic study, on the initiative of Pr Habré, University of Geneva, will analyze the safety profile of dexamethasone after tonsillectomy in children compared to placebo. We are currently submitting this study to our Ethics Committee, as well as to the Belgian authorities. In that, we can act as National Coordinator for this study. If you would like to participate in this study, please send us an email with your contact details as soon as possible before March 10th. We can then include your center in the submission. Please refer to the leaflet available here for further information.
Please send your mail to: françoise.email@example.com, who will act as National Coordinator.
Do not send an email to the Swiss center as they will not handle the submission in Belgium.
Coronavirus Safety Guidelines
In light of the recent outbreak of coronavirus (COVID-19), WFSA has uploaded a new resource outlining safety guidelines for anaesthesia and perioperative care providers. This resource will be updated if and when more information becomes available. Please find more information here.
Issue 1 – Fall 2019 is available here.
A prospective multi-centre international observational study of postoperative vasopressor use
Honor to Philippe Baele
Syndromes & rare diseases in Pediatrics: Anesthesia
Syndromes et maladies rares en anesthésie pédiatrique
Very important website in emergency situations when there is few time to go through the literature to find which could be the anesthetic implications of a syndrome or a rare condition presented by a pediatric patient.
Communication regarding the new measures to emphasize the existing limitations of Hydroxyetheyl starch-containing genomic drugs
Graag informeren wij u over het feit dat de opdruk op de Durogesic pleisters voor transdermaal gebruik is aangepast; de pleisters zullen een gekleurde rand bevatten. De pleisters met het nieuwe ontwerp zullen beschikbaar zijn op de markt vanaf eind november. Klik hier voor meer informatie.
On tient à vous signaler que l’impression figurant sur les dispositifs transdermiques Durogesic a été adaptée ; les patchs comporteront dorénavant un bord coloré.
Les nouveaux patchs adaptés seront disponibles sur le marché dès la fin novembre. Cliquez-ici.